Tethys tethers Lipomics
This article was originally published in The Gray Sheet
Diagnostics start-up Tethys Bioscience acquires Lipomics Technologies Sept. 17 for an undisclosed sum to shore up its technology know-how to create new tests beyond its first diabetes risk assessment tool, launched earlier this year. Tethys' PreDx test, which measures levels of several proteins in a patient's blood to calculate a score identifying their risk for developing diabetes, relies on the firm's expertise with protein biomarkers. Lipomics, on the other hand, specializes in profiling lipids, which can be evaluated in combination with proteins as an effective risk assessment tool for chronic conditions, Tethys says. Lipomics' current business centers on contracting to perform biomarker research for drug company development projects, partnerships that could be helpful to Tethys' plan to establish drug-diagnostic co-marketing agreements (1"The Gray Sheet" July 28, 2008, p. 16)
You may also be interested in...
Diagnostics start-up Tethys Bioscience is laying the groundwork for its first product - a lab test it says will improve screening of the more than 50 million people at near-term risk for developing type-2 diabetes and help identify the best candidates for early-stage intervention
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.